Ralinepag Clinical Trials (2026): 5 Studies for Pulmonary Arterial Hypertension & Vascular Diseases
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Ralinepag clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Pulmonary Arterial Hypertension & Vascular Diseases) and 1,757 total planned enrollment. 3 Phase 3 Ralinepag trials and 1 Phase 2 are listed. 1 Ralinepag clinical trial is actively recruiting. Most recent activity: NCT03683186 (Dec 2026).
Ralinepag clinical trials at a glance: phase × recruitment status
| Phase | enrolling by invitation | completed | terminated | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | 1 | 3 |
Recruiting Ralinepag clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | P3 | PAH | 1,000 | Sep 2019 |
Ralinepag clinical trials by indication
PAH (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03683186 | — | P3 | enrolling by invitation | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension |
| NCT03626688 | — | P3 | completed | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients |
| NCT04084678 | CAPACITY | P3 | terminated | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH |
Healthy Volunteer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04613999 | — | P1 | completed | A Study of Ralinepag in Healthy Chinese Adult Subjects |
Pulmonary Arterial Hypertension (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02279745 | — | P2 | completed | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension |
Ralinepag pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CAPACITY | NCT04084678 | P3 | terminated | PAH | 10 | — |
Terminated and withdrawn Ralinepag trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04084678terminatedA Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
All Ralinepag trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | P3 | enrolling by invitation | 1,000 | United Therapeutics | Sep 2019 | |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | P3 | completed | 687 | United Therapeutics | Aug 2018 | |
| NCT04084678 | CAPACITY | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH | P3 | terminated | 10 | United Therapeutics | Jan 2021 |
| NCT02279745 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | P2 | completed | 45 | United Therapeutics | Jul 2015 | |
| NCT04613999 | A Study of Ralinepag in Healthy Chinese Adult Subjects | P1 | completed | 15 | Everstar Medicines (Shanghai) Limited | Oct 2020 |
Ralinepag clinical trials: frequently asked questions
- How many Ralinepag clinical trials are there?
- 5 Ralinepag clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 3 are marked completed.
- Are Ralinepag clinical trials recruiting in 2026?
- Yes — 1 Ralinepag trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ralinepag being studied for?
- Ralinepag is being studied for Pulmonary Arterial Hypertension, Vascular Diseases, PAH, Pulmonary Hypertension, Respiratory Tract Disease and 9 more. The trials are grouped by indication on this page.
- What phase is Ralinepag in?
- Ralinepag clinical trials span 3 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ralinepag clinical trials?
- The lead sponsor across the most Ralinepag trials is United Therapeutics, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ralinepagas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: